Details of the Drug

General Information of Drug (ID: DMEVYHR)

Drug Name
PF-07901801
Synonyms maplirpacept
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2 [1]
Ovarian cancer 2C73 Phase 1/2 [2]
Drug Type
Fusion protein
Cross-matching ID
UNII
44D51T6SZH
DrugBank ID
DB18441
TTD ID
D6SJ0B
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD47-SHPS1 interaction (CD47-SHPS1 PPI) TTZPFCG CD47_HUMAN-SHPS1_HUMAN Inhibitor [1]
Leukocyte surface antigen CD47 (CD47) TT28S46 CD47_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05261490) A Phase 1/2 Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. U.S.National Institutes of Health.